Enhancing Vaccine Safety Surveillance: A capture-recapture analysis of intussusception after rotavirus vaccination

被引:52
|
作者
Verstraeten, T
Baughman, AL
Cadwell, B
Zanardi, L
Haber, P
Chen, RT
机构
[1] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA USA
[2] Ctr Dis Control & Prevent, Vaccine Safety & Dev Act, Div Epidemiol & Surveillance, Natl Immunizat Program, Atlanta, GA USA
[3] Ctr Dis Control & Prevent, Div Data Management, Natl Immunizat Program, Atlanta, GA USA
[4] Ctr Dis Control & Prevent, Child Vaccine Preventable Dis Branch, Div Epidemiol & Surveillance, Natl Immunizat Program, Atlanta, GA USA
[5] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA
关键词
intussusception; rotavirus; vaccines;
D O I
10.1093/aje/154.11.1006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The Vaccine Adverse Event Reporting System (VAERS) is the passive reporting system for postmarketing surveillance of vaccine safety in the United States. The proportion of cases of an adverse event after vaccination that are reported to VAERS (i.e., VAERS reporting completeness) is mostly unknown. Therefore, the risk of such an event cannot be derived from VAERS only. To study whether its reporting sensitivity and risks could be estimated, VAERS was linked to data from a case-control and a retrospective cohort study in a capture-recapture analysis of intussusception after rotavirus vaccination (RV). Cases of intussusception after RV were selected from the common time frame (December 1998 through June 1999) and the common geographic area (19 states) of the three sources. Matching occurred on birth date, gender, state, date of vaccination, and date of diagnosis. Thirty-five matches were identified among a total of 84 cases. The estimated VAERS reporting completeness was 47%. The relative risks of intussusception in the periods 3-7 and 8-14 days after RV (relative risk = 22.7 and 4.4, respectively) were comparable with those reported in the two studies. Linkage of VAERS to complimentary data sources may permit more timely postmarketing assessment of vaccine safety.
引用
收藏
页码:1006 / 1012
页数:7
相关论文
共 50 条
  • [21] Postmarketing Surveillance of Intussusception Following Mass Introduction of the Attenuated Human Rotavirus Vaccine in Mexico
    Raul Velazquez, F.
    Colindres, Romulo E.
    Grajales, Concepcion
    Teresa Hernandez, M.
    Guadalupe Mercadillo, Maria
    Javier Torres, F.
    Cervantes-Apolinar, MariaYolanda
    DeAntonio-Suarez, Rodrigo
    Ortega-Barria, Eduardo
    Blum, Maxim
    Breuer, Thomas
    Verstraeten, Thomas
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (07) : 736 - 744
  • [22] Post-marketing safety surveillance of the rotavirus vaccine in India
    Kang, Gagandeep
    Lakhkar, Anand
    Bhamare, Chetanraj
    Dharmadhikari, Abhijeet
    Narwadkar, Jyoti
    Kanujia, Arti
    Desai, Sajjad
    Gunale, Bhagwat
    Poonawalla, Cyrus S.
    Kulkarni, Prasad S.
    VACCINE: X, 2023, 15
  • [23] Childhood Intussusception after Introduction of Indigenous Rotavirus Vaccine: Hospital-Based Surveillance Study from Odisha, India
    Subal Kumar Pradhan
    Mrutunjay Dash
    Rajib Kumar Ray
    Nirmal Kumar Mohakud
    Rashmi Ranjan Das
    Saroj Kumar Satpathy
    Jasashree Chaudhury
    J. Bikrant Prusty
    Pooja Sagar Padhi
    Subrat Kumar Mohanty
    Mirabai Das
    Samarasimha Reddy N
    Manas Kumar Nayak
    The Indian Journal of Pediatrics, 2021, 88 : 112 - 117
  • [24] Childhood Intussusception after Introduction of Indigenous Rotavirus Vaccine: Hospital-Based Surveillance Study from Odisha, India
    Pradhan, Subal Kumar
    Dash, Mrutunjay
    Ray, Rajib Kumar
    Mohakud, Nirmal Kumar
    Das, Rashmi Ranjan
    Satpathy, Saroj Kumar
    Chaudhury, Jasashree
    Prusty, J. Bikrant
    Padhi, Pooja Sagar
    Mohanty, Subrat Kumar
    Das, Mirabai
    Reddy, Samarasimha N.
    Nayak, Manas Kumar
    INDIAN JOURNAL OF PEDIATRICS, 2021, 88 (SUPPL 1) : 112 - 117
  • [25] Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India
    John, Jacob
    Kawade, Anand
    Rongsen-Chandola, Temsunaro
    Bavdekar, Ashish
    Bhandari, Nita
    Taneja, Sunita
    Antony, Kalpana
    Bhatnagar, Veereshwar
    Gupta, Arun
    Kabra, Madhulika
    Kang, Gagandeep
    VACCINE, 2014, 32 : A104 - A109
  • [26] Post-licensure passive safety surveillance of rotavirus vaccines: Reporting sensitivity for intussusception
    Perez-Vilar, S.
    Diez-Domingo, J.
    Gomar-Fayos, J.
    Pastor-Villalba, E.
    Sastre-Canton, M.
    Puig-Barbera, J.
    ANALES DE PEDIATRIA, 2014, 81 (02): : 77 - 85
  • [27] Risk of intussusception following rotavirus vaccination: An evidence based meta-analysis of cohort and case-control studies
    Kassim, Priya
    Eslick, Guy D.
    VACCINE, 2017, 35 (33) : 4276 - 4286
  • [28] The Apparent Lack of the Risk of Intussusception Immediately After Rotavirus Vaccination Among Japanese Infants
    Kikuchi, Wakako
    Noguchi, Atsuko
    Sato, Yoko
    Konno, Yuuki
    Komatsu, Akira
    Tandai, Satoru
    Kikuchi, Wataru
    Miura, Shinobu
    Fukaya, Hiroshi
    Ohata, Tomoaki
    Noguchi, Hiroo
    Matsuno, Kenichi
    Tsukahara, Hisayuki
    Kondo, Daiki
    Komatsu, Masaki
    Tamura, Masamichi
    Koizumi, Hiromi
    Nakagomi, Toyoko
    Nakagomi, Osamu
    Takahashi, Tsutomu
    VIRUSES-BASEL, 2024, 16 (11):
  • [29] Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination
    Niu, MT
    Erwin, DE
    Braun, MM
    VACCINE, 2001, 19 (32) : 4627 - 4634
  • [30] Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia
    Buttery, J. P.
    Danchin, M. H.
    Lee, K. J.
    Carlin, J. B.
    McIntyre, P. B.
    Elliott, E. J.
    Booy, R.
    Bines, J. E.
    VACCINE, 2011, 29 (16) : 3061 - 3066